Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 3024-3032

  Chen, Lihong ^a,b   Miao, Yifei ^a,b   Zhang, Yahua ^c   Dou, Dou ^a   Liu, Limei ^a   Tian, Xiaoyu ^d   Yang, Guangrui ^b   Pu, Dan ^b   Zhang, Xiaoyan ^b   Kang, Jihong ^b   Gao, Yuansheng ^a   Wang, Shiqiang ^e   Breyer, Matthew D ^c   Wang, Nanping ^b   Zhu, Yi ^a,b   Huang, Yu ^d   Breyer, Richard M ^c   Guan, Youfei ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e PEKING UNIVERSITY   (China)

Author keywords

angiotensin II; calcium; E prostanoid 3; hypertension; vasoconstriction

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; ANGIOTENSIN II; CALCIUM; PROSTAGLANDIN E RECEPTOR 3; SULPROSTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY CATHETERIZATION; ARTERY MUSCLE CONTRACTILITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CAROTID ARTERIAL CATHETERIZATION; CONTROLLED STUDY; GENOTYPE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE CONTRACTILITY; WILD TYPE;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CALCIUM; CELLS, CULTURED; GENE DELETION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; VASOCONSTRICTION;

EID: 84870056997     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.254052     Document Type: Article

References (51)

1. Breyer MD, Breyer RM. G proteincoupled prostanoid receptors and the kidney. Annu Rev Physiol. 2001;63:579-605.
2. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004;43:525-530. (Pubitemid 38282421)
3. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147-166. (Pubitemid 39209041)
4. Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1 and 2derived prostanoids in mouse kidney and aorta. Hypertension. 2006;48:323-328. (Pubitemid 44309830)
5. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 2002;6869:557-573. (Pubitemid 35247420)
6. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193-1226. (Pubitemid 29473315)
7. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins. 1994;47:151-168. (Pubitemid 24089361)
8. Kennedy I, Coleman RA, Humphrey PP, Levy GP, Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982;24:667-689. (Pubitemid 13217216)
9. Lawrence RA, Jones RL. Investigation of the prostaglandin E (EP) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol. 1992;105:817-824.
10. Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem. 1993;268:20175-20178. (Pubitemid 23278918)
11. Funk CD, Furci L, FitzGerald GA, Grygorczyk R, Rochette C, Bayne MA, Abramovitz M, Adam M, Metters KM. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem. 1993;268:26767-26772. (Pubitemid 23361766)
12. Irie A, Sugimoto Y, Namba T, Harazono A, Honda A, Watabe A, Negishi M, Narumiya S, Ichikawa A. Third isoform of the prostaglandinEreceptor EP3 subtype with different Cterminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem. 1993;217:313-318. (Pubitemid 23305301)
13. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A, Ito S, Ichikawa A, Narumiya S. Alternative splicing of Cterminal tail of prostaglandin E receptor subtype EP3 determines Gprotein specificity. Nature. 1993;365:166-170. (Pubitemid 23282063)
14. Negishi M, Namba T, Sugimoto Y, Irie A, Katada T, Narumiya S, Ichikawa A. Opposite coupling of prostaglandin E receptor EP3C with Gs and G(o). Stimulation of Gs and inhibition of G(o). J Biol Chem. 1993;268:26067-26070. (Pubitemid 23361666)
15. Sugimoto Y, Negishi M, Hayashi Y, Namba T, Honda A, Watabe A, Hirata M, Narumiya S, Ichikawa A. Two isoforms of the EP3 receptor with different carboxylterminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem. 1993;268:2712-2718. (Pubitemid 23057900)
16. Yang J, Xia M, Goetzl EJ, An S. Cloning and expression of the EP3subtype of human receptors for prostaglandin E2. Biochem Biophys Res Commun. 1994;198:999-1006.
17. Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem. 2002;131:781-784. (Pubitemid 34717580)
18. Guan Y, Zhang Y, Wu J, et al. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007;117:2496-2505. (Pubitemid 47494351)
19. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, Breyer RM. Saltsensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999;5:217-220. (Pubitemid 29068530)
20. Zhu S, Xue R, Zhao P, Fan FL, Kong X, Zheng S, Han Q, Zhu Y, Wang N, Yang J, Guan Y. Targeted disruption of the prostaglandin E2 Eprostanoid 2 receptor exacerbates vascular neointimal formation in mice. Arterioscler Thromb Vasc Biol. 2011;31:1739-1747.
21. Hristovska AM, Rasmussen LE, Hansen PB, Nielsen SS, Nüsing RM, Narumiya S, Vanhoutte P, Skøtt O, Jensen BL. Prostaglandin E2 induces vascular relaxation by Eprostanoid 4 receptormediated activation of endothelial nitric oxide synthase. Hypertension. 2007;50:525-530. (Pubitemid 47312239)
22. Zhang Y, Guan Y, Schneider A, Brandon S, Breyer RM, Breyer MD. Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension. 2000;35:1129-1134. (Pubitemid 30327269)
23. Guan Y, Zhang Y, Wu J, et al. Antihypertensive effects of selective prostaglandin E(2) receptor subtype 1 targeting. J Clin Invest. 2007;117:2496-2505. (Pubitemid 47494351)
24. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rhokinase signaling in the vasculature: highlights from the recent literature. Hypertension. 2004;44:796-799. (Pubitemid 39577399)
25. Tilley SL, Audoly LP, Hicks EH, Kim HS, Flannery PJ, Coffman TM, Koller BH. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest. 1999;103:1539-1545.
26. Hockel GM, Cowley AW Jr. Prostaglandin E2induced hypertension in conscious dogs. Am J Physiol. 1979;237:H449-H454. (Pubitemid 10249647)
27. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, Kim HS, Flannery PJ, Coffman TM, McNeish JD, Audoly LP. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest. 2001;107:325-331. (Pubitemid 32157964)
28. Ariumi H, Takano Y, Masumi A, Takahashi S, Hirabara Y, Honda K, Saito R, Kamiya HO. Roles of the central prostaglandin EP3 receptors in cardiovascular regulation in rats. Neurosci Lett. 2002;324:61-64. (Pubitemid 34442678)
29. Höcherl K, Kammerl MC, Schumacher K, Endemann D, Grobecker HF, Kurtz A. Role of prostanoids in regulation of the reninangiotensinaldosterone system by salt intake. Am J Physiol Renal Physiol. 2002;283:F294-F301. (Pubitemid 34778992)
30. Kawada N, Solis G, Ivey N, Connors S, Dennehy K, Modlinger P, Hamel R, Kawada JT, Imai E, Langenbach R, Welch WJ, Wilcox CS. Cyclooxygenase1deficient mice have high sleeptowake blood pressure ratios and renal vasoconstriction. Hypertension. 2005;45:1131-1138. (Pubitemid 40770317)
31. Ye W, Zhang H, Hillas E, Kohan DE, Miller RL, Nelson RD, Honeggar M, Yang T. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol. 2006;290:F542-F549. (Pubitemid 43725008)
32. Mtabaji JP, Kihara M, Yamori Y. The effects of indomethacin and PGE2 on vascular reactivity in spontaneously hypertensive rats: possible role of prostaglandins in the pathogenesis of hypertension. Prostaglandins Leukot Med. 1985;20:255-265. (Pubitemid 16210817)
33. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda). 2009;24:342-356.
34. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotideexchange factors. Nat Rev Mol Cell Biol. 2005;6:167-180. (Pubitemid 40215811)
35. An S, Yang J, So SW, Zeng L, Goetzl EJ. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry. 1994;33:14496-14502.
36. Irie A, Segi E, Sugimoto Y, Ichikawa A, Negishi M. Mouse prostaglandin E receptor EP3 subtype mediates calcium signals via Gi in cDNAtransfected Chinese hamster ovary cells. Biochem Biophys Res Commun. 1994;204:303-309. (Pubitemid 24335296)
37. Shum WW, Le GY, Jones RL, Gurney AM, Sasaki Y. Involvement of Rhokinase in contraction of guineapig aorta induced by prostanoid EP3 receptor agonists. Br J Pharmacol. 2003;139:1449-1461. (Pubitemid 37174659)
38. Ying Z, Jin L, Palmer T, Webb RC. Angiotensin II upregulates the leukemiaassociated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domaincontaining RhoGEF, in vascular smooth muscle cells. Mol Pharmacol. 2006;69:932-940. (Pubitemid 43363867)
39. Guilluy C, Brégeon J, Toumaniantz G, RolliDerkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183-190.
40. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, KimMitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, Nakashima H, Woolfolk EA, Motley ED, Eguchi S. Signalcrosstalk between Rho/ROCK and cJun NH2terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol. 2005;25:1831-1836. (Pubitemid 41243450)
41. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68-75. (Pubitemid 30054239)
42. Purdy KE, Arendshorst WJ. Prostaglandins buffer ANG IImediated increases in cytosolic calcium in preglomerular VSMC. Am J Physiol. 1999;277(6 Pt 2):F850-F858. (Pubitemid 30046059)
43. Satoh H, Satoh S. Prostaglandin E2 and I2 production in isolated dog renal arteries in the absence or presence of vascular endothelial cells. Biochem Biophys Res Commun. 1984;118:873-876. (Pubitemid 14194798)
44. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase1 and 2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69. (Pubitemid 34743466)
45. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensinIIinduced hypertension. Hypertension. 2004;43:364-369. (Pubitemid 38174140)
46. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the reninangiotensin system. J Clin Invest. 2005;115:1092-1099. (Pubitemid 40489414)
47. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007;49:1196-1201. (Pubitemid 46809352)
48. Kurdi M, Booz GW. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension. 2011;57:1034-1038.
49. Shinmura K, Tamaki K, Sato T, Ishida H, Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATPsensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol. 2005;288:H2093-H2101. (Pubitemid 40604092)
50. Zhang ZH, Yu Y, Wei SG, Nakamura Y, Nakamura K, Felder RB. EP3 receptors mediate PGE2induced hypothalamic paraventricular nucleus excitation and sympathetic activation. Am J Physiol Heart Circ Physiol. 2011;301:H1559-H1569.
51. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617. (Pubitemid 47100657)